In his written statement to the Inquiry, Dr Boulton explained that "'litigation' should be viewed as a sort of surrogacy for 'responsible practices'", which would involve balancing the need to secure clinical supplies of donor blood with patient welfare and the minimisation of risk, even using an imperfect testing method.